DIGITAL HEALTH INTELLIGENCE REPORT COLLECTION
How can commercial teams unlock new opportunities with RWE?
RWE can deliver commercial value across a product’s lifecycle from informing research and identifying medical need to the effective deployment of sales forces and commercial strategy refinement. So how can RWE be used to prove value and secure regulatory approval? In what ways can RWE inform patient segmentation? What role can RWE play in post-marketing surveillance and product enhancement?
In The Value of RWE to Commercial Teams industry experts reveal how RWE can transform commercial practice, the key areas for action and the challenges that commercial teams will face.
Report Overview
Advanced medical wearables now comprise smart patches, smart rings, smart garments and smart ear buds and the emergence of validated medical-grade technology in consumer devices is seen as critical in delivering the next generation of wearables. Regulators are supportive and payers are seeing the contribution wearables can make to lowering the overall cost of health.
So, how can pharma benefit? In Innovations in Wearables for Digital Health digital health experts review the current wearables sector, examine the technologies that will shape the future and identify the challenges and areas of opportunity for pharma.
Key Therapies Covered
Bavencio (avelumab)
Keytruda (pembrolizumab)
Opdivo (nivolumab)
Tecentriq (atezolizumab)
Imfinzi (durvalumab)
Cabometyx (cabozantinib)
Fotivda (tivozanib)
Inlyta (axitinib)
Lenvima/Kisplyx (lenvatinib)
Sutent (sunitinib)
Votrient (pazopanib)
Afinitor (everolimus)
abexinostat
MK-6482
bempegaldesleukin
Content Highlights
- Subject synopsis
- Research methodology and objectives
- Key insights summary
- Issues and insights
What Our Clients Are Saying
“Excellent”
Director, Medical Affairs, AstraZeneca
“...this report has been very valuable”
Director, Biotech New Product Planning and Drug Delivery, Eli Lilly
Contact Us
© 2022 FirstWord. All rights reserved | 1140 Avenue of the Americas, 14th Floor, New York, NY 10036
Partial List of Participating KOLs
Deputy Director
Georgetown Lombardi Comprehensive Cancer Center, and the Scholl Professor and vice chair of the Department of Medical Oncology at Georgetown University Medical Center, Georgetown University School of Medicine, Washington, DC
Associate Professor of Oncology
Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY
Professor
Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Head of the Medical Oncology Department
Hospital Universitario Central de Asturias, Oviedo, Spain
Professor of Medicine
Head of the SS Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Professor of Oncology and Chief of the Oncology
Clinical and Translational Research Unit at Georges Pompidou Hospital, Paris, France
Our Research
We engage the world’s leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
Our in-house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
View A Full List Of Therapy Trends Reports
Leading KOLS
KOL Answers
Future Focused
The Value of RWE to Commercial Teams
RWE experts answer key questions
Expert Contributors
- Paying for Value
- Building on success of value-based approaches in health care
- Drug VBCs are a priority for some payers
- Choosing the right products
- Manufacturer competence needed for VBC
- Choosing the right payer to work with on a VBC
- VBCs can be offered at launch
- Technology is enabling VBCs
- Piloting VBCs
- Choosing the VBCs to publicize
- The challenges in scaling up use of VBCs
Each issue addressed is broken down into the following subsections
- Issue summary
- Questions
- Key insights
- Expert quotes
- Intelligence exhibits
Content highlights
- Executive level experience in digital health, digital patient services or digital patient support with at least five years of involvement in digital health initiatives.
- At least three years’ experience in the field of digital health, mobile health, or digital capabilities for health.
- Direct experience designing, executing or influencing innovations in wearables for digital health initiatives in the last 18 months.
Overview: Medicare and Medicaid
Manufacturers in 2020
Top 10 branded drugs in 2020
Top 10 non-branded drugs in 2020
Medicare Part D top 50 summary
Top 50 Medicare Part D expenditure
Medicaid pharmaceutical expenditure overview
Manufacturers in 2020
Top 10 branded drugs in 2020
Top ten non-branded drugs in 2020
Top 50 Medicaid expenditure
Graphs and tables for 50 drugs reimbursed by Medicare and Medicaid covering
Product summary and summary data
5-year trends for Medicare expenditure, prescriptions and claimants 2016-2020
Medicare expenditure per prescription and per claimant 2016-2020
Medicaid expenditure for prescriptions and cost per prescription
- What are the top 3 areas of commercial value that RWE offers pre- and post-launch?
- How has RWE redefined the role and practice of commercial teams?
- Are partnerships or acquisitions the most effective strategy for commercial teams investing in RWE?
- In what ways can RWE facilitate engagement between commercial teams and stakeholders and what type of RWE offers the most value for these engagements?
- How are advanced digital and data analytics increasing the value of RWE for commercial teams?
- Distrust of RWE by stakeholders? Data protection? Lack of RWE data standards? What are the barriers to the wider use of RWE and how can they be overcome?
- Joel Beilin, Founder and CEO of Global Audiology Consulting, Denmark
- Giovanni Di Sarro, Senior Business Partner of Global Digital Solutions at Lundbeck, Denmark
- Pierre-Alexandre Fournier, Co-founder of Hexoskin, a leading sensor and AI/analytics company for health, research and medicine
- Serkan Oray, Vice President of Devices, Packaging, & Wearable Technologies at UCB, Belgium
- Panos Papakonstantinou, Global Commercial Director of Mobility Solutions at the Novartis Institutes for BioMedical Research (NIBR), Switzerland
- Gergely Vértes, Solution Accelerator Lead and the Wearable Clinical Project Lead in Epilepsy at UCB Bekgium
- Dr. Jian Yang, Senior Director of Digital Health at Eli Lilly and Company, US
- Anonymous, technology leader, multinational biopharmaceutical company
The RWE experts from companies such as Novartis, Amgen and Sanofi Genzyme who contributed to this research study have been carefully screened to ensure they have at least 5 years’ experience working in a pharma commercial team and at least 3 years’ experience in RWE analytics or have served as a member of a governmental agency or recognised non-governmental organisation concerned with RWE within the pharma industry.
Content Highlights
Identifying the commercial value of RWE
Redefining the role of commercial teams
Partnering and acquiring for RWE commercial value
Convincing stakeholders with RWE
Next-generation RWE
Overcoming RWE challenges
Untapped RWE opportunities
Learn more about this report or how we can support you with additional insights. If you are already a client, log in to read the report.
FirstWord ExpertViews reports reveal the real-world insights of knowledgeable experts to analyse in detail key commercial and market trends that pharma management needs to understand if they are to effectively respond to critical developments
What makes FirstWord ExpertViews reports different?
Relevant to your needs
Boardroom ready
This ExpertViews report is supported by an engaging and accessible slide pack that summarises the core of the research and analysis, making key findings easy to share with colleagues and key stakeholders.
We don’t waste time telling you what you already know. The tight screening of expert contributors ensures you get new, cutting edge and relevant insights to take your practical knowledge to new levels.
Fresh new content
Our reports cover the current developments and trends that will shape future markets and practice, helping you to identify threats and exploit opportunities.
Deep dive
Our research with industry experts results in hundreds of direct quotes, providing you with a first-hand, objective and comprehensive view of key market-shaping issues.
Case studies included in the report
Janssen and Komodo Health partner for RWE-driven clinical development
Roche's RWE-driven acquisition of Flatiron Health
The GetReal Institute: Maintaining best practices in RWE generation
Sanofi’s RWE collaboration with Evidation